News | Stereotactic Body Radiation Therapy (SBRT) | April 28, 2016

New Clinical Trial Applying SBRT to Partial Prostate Gland for Prostate Cancer

Treatment of targeted regions within the prostate in early-stage prostate cancer may increase treatment options and reduce side effects

prostate cancer, partial gland, SBRT, clinical trial, UH Hospitals

April 28, 2016 — Physicians at University Hospitals Seidman Cancer Center (Cleveland) have started a clinical trial using a new form of stereotactic body radiotherapy (SBRT) to deliver radiation to a specific area of a cancerous prostate instead of the entire gland.

The study, the first of its kind in the world, aims to determine if treating a targeted cancer region within the prostate in early-stage prostate cancer can increase treatment options and reduce the side effects of radiation. If successful, the trial could have a significant impact on the standard of care for men diagnosed with low or intermediate risk prostate cancer.

The trial’s first patient was enrolled and underwent therapy earlier this month without any side effects reported to date. The procedure was performed jointly by his urologist, Lee Ponsky, M.D., of the UH Urology Institute and a study co-investigator, and his radiation oncologist Rodney Ellis, M.D.

“Our hypothesis is that this method may offer a viable treatment option for men with early-stage prostate cancer before their cancer advances, while also minimizing or even eliminating life-changing side effects of treatment,” said Ellis, vice chairman, clinical affairs, radiation oncology, and UH Seidman Cancer Center, a co-investigator on the study. “We want to know if response and cure rates using focal radiotherapy within the prostate can achieve two goals: the first, to successfully eliminate localized malignancies when the disease is in extremely early stages, and second, to reduce the treatment’s impact on a patient’s quality of life.”

According to the National Cancer Institute, approximately 80 percent of prostate cancer is identified in the early stages of development, when the lesions are localized within the prostate. Men diagnosed at this stage have two primary treatment options: active surveillance, where the patient simply undergoes regular monitoring, or whole gland therapy, with either surgery or targeted radiation therapy applied to the whole prostate. Due to the prostate’s close proximity to the bladder and the rectum, whole prostate radiotherapy, at the levels needed to eradicate malignancies, has a significant risk of causing side effects for men, including rectal bleeding and erectile dysfunction.

For men who have a single lesion amenable to focal therapy, the trial offers a minimally invasive treatment completed in three sessions over a week using SBRT. The trial is designed to validate the patented methodology used in the study to select the target volume for partial prostate treatment. The investigators hope to limit side effects for surrounding tissue.

“Prostate cancer remains the sole malignancy where treatment is always delivered to the whole organ in routine practice,” said Mitchell Machtay, M.D., chairman of the Department of Radiation Oncology at UH Case Medical Center and Case Western Reserve University School of Medicine, and principal investigator of the new study. “It is time to investigate new and better options for low-risk prostate cancer patients. Radiology advancements in ultrasound, CT [computed tomography] and MRI [magnetic resonance imaging] enable us to accurately identify, measure and target malignancies more precisely than ever before.”

The study will enroll 12 patients who will be selected using a patented methodology, owned by University Hospitals and developed in part by Ellis, who is also associate professor of radiation oncology at the School of Medicine.

Philips Medical Systems has licensed this technology and is supporting the study along with Elekta and Invivo.

For more information: www.uhhospitals.org

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...